NCT00258895View on ClinicalTrials.gov

Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®

PHASE3CompletedINTERVENTIONAL

Enrollment

649

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

April 30, 2007

Conditions

DiphtheriaTetanusPertussis

Interventions

BIOLOGICAL

DAPTACEL®: DTaP

0.5 mL, Intramuscular

BIOLOGICAL

DAPTACEL®: DTaP

0.5 mL, Intramuscular

Trial Locations (22)

15213

Pittsburgh

15241

Pittsburgh

Unknown

Fayetteville

Jonesboro

Little Rock

Fountain Valley

Centennial

Norwich

Marietta

Bardstown

Bossier City

Rochester

Pembroke

Sylva

Norristown

Kingsport

Fort Worth

San Antonio

Provo

Spokane

La Crosse

Marshfield

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00258895 - Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL® | Biotech Hunter | Biotech Hunter